Compare Becton Dickinson and Co (BDX) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Xpeng Inc - ADR — how do they compare? Becton Dickinson and Co trades at $180.01 (market cap $49.41B), while Xpeng Inc - ADR trades at $11.77 (market cap $11.15B). The key difference: Becton Dickinson and Co is far larger — about 4.4× Xpeng Inc - ADR's market cap, and Becton Dickinson and Co pays a 2.32% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals.
| BDX | XPEV | |
|---|---|---|
Market Cap | $49.41B | $11.15B |
Sector | Health | Consumer Cyclical |
52-Week High | $185.39 | $28.07 |
52-Week Low | $138.62 | $11.68 |
Enterprise Value | $65.51B | $13.28B |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $179.63, up 1.57% with a bullish technical outlook supported by moving averages. The company reported strong Q3 2026 earnings, beating estimates with $3.23 EPS versus $3.14 expected, and raised full-year guidance. Revenue growth remains steady at 4.4% FX-neutral, though margins face pressure from tariffs. Analysts maintain a mixed consensus with 47% buy ratings and a $183 price target, suggesting modest upside from current levels.
The stock presents a balanced opportunity with solid fundamentals and dividend stability, but faces headwinds from margin compression and competitive pressures. Near-term catalysts include continued execution on growth initiatives, while risks include tariff impacts and healthcare regulatory changes. The current valuation at 31.39 P/E appears fair given growth prospects.
XPeng (XPEV) trades at $12.00, down 1.07% on the day, with a bearish technical signal. The company reported Q1 2026 revenue of $76.72 billion but a net loss of $1.14 billion, though the net margin improved to -1.49% from -14.17% in 2024. Recent news highlights vehicle delivery growth, international expansion, and advancements in autonomous driving technology.
The outlook is mixed: strong revenue growth and analyst buy ratings (64.7% consensus) suggest upside to the $17.00 price target, but persistent losses, high EV/EBITDA of 40.09, and competitive pressures pose risks. Investor sentiment is cautious amid earnings volatility and macroeconomic headwinds in the EV sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
